Last Update 21 Apr 26

XAIR: Later Regulatory Decision Will Still Support Long Term Upside Potential

Analysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset.

Analyst Commentary

Bullish Takeaways

Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.
The continued Buy rating signals confidence that, if commercialization of the second generation LungFit PH occurs as planned, the current share price may already reflect a conservative view of future execution.
Supportive views focus on the idea that a clear FDA decision timeline, even if extended, can reduce some uncertainty around the path to potential revenue scale up.
Some bullish analysts frame the lower price target as a reset that better aligns expectations with the revised sales outlook and approval timing, rather than a shift in their core thesis on the product opportunity.

Bearish Takeaways

Bearish analysts highlight that the cut in sales estimates for the LungFit PH platform, combined with the extended FDA decision timeline to the end of 2026, raises execution risk around achieving meaningful revenue growth.
The move to a US$2 price target reflects concerns that a longer path to potential commercialization may weigh on sentiment and limit near term valuation support.
Cautious views focus on the possibility that additional delays or regulatory hurdles could further pressure expectations for both revenue ramp and profitability.
Some bearish analysts are concerned that a more drawn out commercialization path may require additional resources to sustain operations, which could affect shareholder dilution and the equity story.

What's in the News

Nasdaq notified Beyond Air on April 7, 2026 that the company no longer meets the US$1.00 minimum bid price requirement for continued listing, and its shares are subject to potential delisting unless it requests a hearing by April 14, 2026 (Nasdaq notice).
Beyond Air plans to request a hearing before the Nasdaq Hearings Panel, which would pause any suspension or delisting while the Panel reviews the case, and is considering options such as another reverse stock split to regain compliance (Nasdaq notice).
Effective April 1, 2026, Beyond Air was awarded a national group purchasing agreement for inhaled nitric oxide therapy that gives participating U.S. hospitals and health systems access to the LungFit PH system, expanding reach across multiple large group purchasing organizations (company announcement).
The new agreement complements existing relationships with Vizient and Premier, creating a broader channel for hospitals to consider a tankless nitric oxide solution that aims to simplify workflows and reduce supply chain burden (company announcement).
On March 26, 2026, Beyond Air appointed Robert Goodman as Chief Executive Officer, following the resignation of prior CEO Steve Lisi, with Goodman stepping up from his role as Chief Commercial Officer and board member (company announcement).

Valuation Changes

Fair Value: $8.67 per share is unchanged, and the updated model keeps the same estimated intrinsic value as before.
Discount Rate: 12.33% remains the same, so the required return used in the model is consistent with the prior assessment.
Revenue Growth: Forecast revenue growth has risen from 75.82% to 96.89%, indicating a higher assumed pace of future dollar sales expansion.
Net Profit Margin: Assumed net profit margin has edged lower from 13.33% to 12.70%, implying slightly lower expected profitability on each dollar of revenue.
Future P/E: The future P/E multiple has been reduced from 29.38x to 21.96x, pointing to a lower valuation multiple being applied to projected earnings.

3 views

Key Takeaways

International expansion and partnerships are driving greater market access, positioning the company for sustained revenue growth in advanced respiratory care.
Product innovation and operational efficiencies are improving scalability, margin potential, and revenue stability through recurring contracts and long-term customer relationships.
Heavy reliance on a single core platform, ongoing losses, and competitive pressures expose Beyond Air to revenue volatility, margin risks, and potential shareholder dilution.

Catalysts

About Beyond Air

A commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.What are the underlying business or industry changes driving this perspective?

Strong global expansion with distribution partners now covering over 30 countries and access to more than 2 billion people positions Beyond Air to capitalize on the growing demand for advanced respiratory care fueled by aging populations and rising healthcare expenditures, likely driving sustained revenue growth.
Integration into two of the largest U.S. Group Purchasing Organizations (Vizient and Premier) lowers sales cycle friction and improves market access, aligning with the increasing emphasis on non-pharmaceutical interventions in respiratory care and enhancing the company's ability to scale recurring revenues.
Upcoming launch of the second-generation LungFit system, designed for portability and broader hospital use, responds to digital health transformation trends and is expected to significantly boost market share, total nitric oxide volumes, and eventually improve gross and net margins as adoption accelerates.
Substantial operational cost reductions (over 40% YoY decrease in operating expenses and 60% drop in cash burn) have created operating leverage; as new revenues ramp with international and domestic expansion, incremental sales should increasingly flow to earnings.
The transition to multiyear and recurring hospital contracts, together with longer-term customer relationships and expanding use-cases, supports revenue stability and visibility, which is a tailwind for improving margin and earnings quality over time.

Beyond Air Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Beyond Air's revenue will grow by 96.9% annually over the next 3 years.
Analysts are not forecasting that Beyond Air will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Beyond Air's profit margin will increase from -447.7% to the average US Medical Equipment industry of 12.7% in 3 years.
If Beyond Air's profit margin were to converge on the industry average, you could expect earnings to reach $6.7 million (and earnings per share of $0.52) by about April 2029, up from -$31.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 23.6x on those 2029 earnings, up from -0.2x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.2x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 12.33%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Beyond Air remains heavily reliant on one core platform (LungFit PH and its upcoming Gen II version); delays in FDA approval or underperformance in clinical adoption of the Gen II system could significantly constrain revenue growth, limit margin expansion, and increase earnings volatility.
The company continues to post material net losses (Q1 2026 net loss of $7.7 million), with cash and equivalents of just $6.5 million as of June 30, 2025-raising substantial dilution risk if internal projections are missed or costs rise, thus putting pressure on future per-share earnings and overall shareholder returns.
Entry into large US hospital systems via group purchasing organizations (GPOs) like Premier and Vizient may compress ASPs and extend sales cycles as buyers gain negotiating leverage, posing potential headwinds to sustained top-line growth and long-term gross margins.
International expansion is still in early, unproven stages; sales so far are primarily to distribution partners for demonstration/training, and actual hospital adoption is likely to lag by several quarters, creating long cycles before material recurring revenues may be realized and increasing revenue forecasting risk.
Industry-wide pressures around healthcare cost containment and rising competition from both large device manufacturers and agile startups in respiratory care could threaten Beyond Air's market share, compress pricing power, and undermine net margin improvement over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $8.67 for Beyond Air based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $2.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $52.8 million, earnings will come to $6.7 million, and it would be trading on a PE ratio of 23.6x, assuming you use a discount rate of 12.3%.
Given the current share price of $0.55, the analyst price target of $8.67 is 93.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Beyond Air?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

XAIR: Global Network Expansion Will Drive Long-Term Market Presence